What Elutia Inc. does.

At Elutia, our mission is to humanize medicine so that patients can thrive without compromise. We develop proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Our focus is on addressing unmet medical needs and reducing complications associated with surgery, including infection, migration, erosion, implant rejection, and fibrosis. Our operations span research and development through the commercial distribution of biologic matrix products used in plastic and reconstructive surgery.

We have applied these capabilities to develop and commercialize products for specific surgical applications. As more fully described below, on October 1, 2025, we divested one such product family through the sale of substantially all of the assets related to our business of developing, commercializing, manufacturing, selling and marketing our cardiac implantable electronic device (“CIED”) products, EluPro™ and CanGaroo®, to Boston Scientific Corporation (“BSC”) and Cardiac Pacemakers Inc (“CPI”) for an aggregate purchase price of up to $88.0 million in cash. EluPro was the first antibiotic-eluting biologic matrix envelope for use with CIEDs. This transaction reflects the technical and commercial value of solutions developed using our biologic matrices and local drug delivery capabilities.

Revenue and profit, by fiscal year.

More on ELUT.

• Elutia Inc. summary
• Elutia Inc. financial statements
• Elutia Inc. key metrics
• Elutia Inc. health scores and style box
• Elutia Inc. earnings
• Elutia Inc. dividends
• Elutia Inc. valuation
• Elutia Inc. ownership and insiders
• Elutia Inc. peers

Figures from Elutia Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.